ORINY - Marinus gets EU approval for anti-seizure treatment Ztalmy

2023-07-31 16:54:37 ET

Marinus Pharmaceuticals ( NASDAQ: MRNS ) and partner Orion Oyj ( OTCPK:ORINY ) said that the European Commission has granted market approval for Marinus's drug Ztalmy as an adjunctive treatment for epileptic seizures in children with CDKL5 deficiency disorder.

The drug was approved for use in patients aged two to 17 and may be continued past age 18. Ztlamy, also known as ganaxolone, is approved in the US for the same indication.

Marinus and Finnish drugmaker Orion entered into an agreement in July 2021 that granted Orion commercialization rights for Ztalmy in Europe.

More on Marinus:

• Marinus gets new method of use patent approval for ganaxolone
• Marinus: Transforming The Seizure Market With Ganaxolone (Rating Upgrade)
• Marinus' seizure drug Ztalmy inches toward EU approval with EMA nod

For further details see: